BrainsWay Ltd.
Company & revenue
About BrainsWay Ltd.
Financial breakdown: year ended 2025-12-31
Who they are
BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets. Its primary offering is the Deep Transcranial Magnetic Stimulation (dTMS) platform technology, which provides treatment for various ailments including major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease.
Brands & revenue mix
The company's primary neurostimulation technology platform.
Reported revenue share.
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Customer concentrationPREMIUM
As of the six months ended June 30, 2025, the company disclosed that one customer accounted for 31% of total revenues.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
54
Fair
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
71
Strong
Financial Strength
42
Business Quality / Moat
100
Management
100
Growth Quality
72
Risk / Durability
25
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
61
Fully Valued
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
65/100
Building Historical Record
Model Score 65/100 — estimates relative performance potential, distinct from WallStreetScore (company quality).
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
WSS currently rates the company as mixed to moderately strong.
At today’s price, the WSS valuation framework currently reads as moderate rather than unusually attractive.
The model outlook is currently moderate.
No strong positive signal is being highlighted from the currently available summary data.
- •Debt service risk
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
Company-specific research
Questions worth answering for BWAY
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can BWAY maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is BWAY's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •How is BWAY likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
Essential Investment Snapshot
Wall Street Score
54
Opportunity Score
61
Market Cap
$490.3M
P/E Ratio
28.7
EPS
$0.46
52-Week High
$17.40
52-Week Low
$7.13
Beta
0.15
Intrinsic Value
$17.71
Analyst Target
$19.50
Shares Outstanding
21.2M
Total Revenue
$61.0M
Total Debt
$7.1M
Dividend
No current dividend
Liquidation Value / Share
$3.73
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for BWAY
Detected from reported data — verify before acting.Debt service risk
Interest coverage is low (~1.9x). Earnings may be strained to cover interest expense.
Community Sentiment
0 active · 0 total callsNo personal call yet on BWAY.
What the Bulls Say
- +Product opportunity: BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets. Its primary offering is the Deep Transcranial Magnetic Stimulation (dTMS) platform technology, which provides treatment for various ailments including major depressive disorders, anxious depression, obsessive-compulsive.
- +Positive free cash flow may provide capacity to invest in growth.
What the Bears Say
No strong bearish data point is currently available.
Bull and bear cases summarize disclosed catalysts, growth opportunities and risks; they are not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
5 historical score records availablePrevious Score
51
Sep 9, 2026
Change
+2.8
points
Current Score
54
Oct 1, 2026
Category Changes
BWAY increased 2.8 points because Valuation improved by 15.4 points.
Positive Contributors
- + Valuation improved by 15.4 points
Projected Score
Projected Score
54
Projected Change
-20.0%
Preliminary comparable-period financial changes suggest decline of approximately 0.2 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
UndervaluedCurrent Price
$12.50
Intrinsic Value
$17.71
Difference
−$5.21
-29.4% vs IV
Margin of Safety
29.4%
Related Companies
Medical - SpecialtiesNews
Brainsway (NASDAQ:BWAY) Shares Gap Down – What’s Next?
BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer's Disease Treated with Deep TMS™
Analyzing Brainsway (NASDAQ:BWAY) and Green Thumb Industries (OTCMKTS:GTBIF)
Wall Street Analysts See a 30.07% Upside in Brainsway (BWAY): Can the Stock Really Move This High?
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial